# Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

> **NCT06691035** · PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (estimated)

## Conditions studied

- Breast Cancer Metastatic Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Elacestrant
- **BIOLOGICAL:** DC1 native/mutated ESR1

## Key facts

- **NCT ID:** NCT06691035
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06691035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06691035, "Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06691035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*